Stocks Health care SLXN
NASDAQ · Health careSilexion Therapeutics Corp (SLXN)
It posted a net loss of $14M. In fiscal 2025 capital spending exceeded operating cash flow by $10.8M. At June 30, 2026 it held $2.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Silexion Therapeutics Corp
- Net worth
- Silexion Therapeutics Corp has a market value (market cap) of $17.5M at the latest share price, and shareholders' equity of $44K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $10.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Silexion Therapeutics Corp does
Silexion Therapeutics Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SLXN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$11.9M | $8.96 | -$10.8M |
| 2024 | n/a | -$16.5M | $394.94 | -$8.4M |
| 2024 | n/a | -$5.1M | $662.68 | -$4.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Silexion Therapeutics Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Proxy statement DEF 14A
- September 30, 2026
- September 29, 2026Material agreement8-KSilexion Therapeutics entered an agreement to reduce warrant exercise prices to raise approximately $0.84 million in gross proceeds.
- September 28, 2026Activist stake changed SCHEDULE 13D/A
- September 28, 2026
- September 25, 2026
- September 25, 2026Preliminary proxy statement PRE 14A
- September 25, 2026
- September 16, 2026Additional proxy material DEFA14A
- September 9, 2026Additional proxy material DEFA14A
Insider trades
What the people running Silexion Therapeutics Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 4, 2026 | Hadar IlanChairman and CEO, Director | Received as pay | 10,000 | - |
| June 4, 2026 | Horenshtein Hadar MiritCFO and Secretary | Received as pay | 7,500 | - |
| June 4, 2026 | Shirvan MitchellCSO and CDO | Received as pay | 6,000 | - |
| March 26, 2026 | Shirvan MitchellCSO and CDO | Sold | 22,818 | $31K |
| February 20, 2026 | Noy ShlomoDirector | Received as payindirect | 9,091 | - |
| February 20, 2026 | Lushi AvnerDirector | Received as payindirect | 9,091 | - |
| February 20, 2026 | Peled AmnonDirector | Received as pay | 7,576 | - |
| February 20, 2026 | Abramov Dror YosefDirector | Received as pay | 9,091 | - |
Who owns SLXN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Moringa Partners Ltd.13D, may seek influence with 3 related filers | 20.8% | August 22, 2024 |
| Moringa Sponsor, LP13D, may seek influence with 2 related filers | 17.7% | September 28, 2026 |
| Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP)13D, may seek influence with 2 related filers | 13.8% | November 20, 2024 |
| Lincoln Alternative Strategies LLC13G, passive | 6.18% | September 15, 2025 |
Largest institutional holders
Insiders
9 insiders reported holding 574,264 shares in total, about $1.8M at the last price.
| Holder | Shares |
|---|---|
| Levin IlanDirector, 10% owner | 456,970456,970 held indirectly |
| Lushi AvnerDirector | 25,39925,399 held indirectly |
| Noy ShlomoDirector | 25,39925,399 held indirectly |
| Hadar IlanChairman and CEO, Director | 16,547 |
| Horenshtein Hadar MiritCFO and Secretary | 12,515 |
| Alon RuthDirector | 10,228 |
| Abramov Dror YosefDirector | 10,180 |
| Shirvan MitchellCSO and CDO | 8,789 |
| Peled AmnonDirector | 8,237 |
Questions about SLXN
What does Silexion Therapeutics Corp do?
Silexion Therapeutics Corp is a company in the Health care sector, listed on NASDAQ as SLXN. Its shares trade on NASDAQ under the ticker SLXN.
What is Silexion Therapeutics Corp's net worth?
Silexion Therapeutics Corp has a market value (market cap) of $17.5M at the latest share price, and shareholders' equity of $44K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Silexion Therapeutics Corp profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $14M.
When did Silexion Therapeutics Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the proxy statement from October 5, 2026.
Similar companies
Compare SLXN with
Follow SLXN
Get an email when Silexion Therapeutics Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Silexion Therapeutics Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.